Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall
Study Details
Study Description
Brief Summary
Patients will receive neoadjuvant sorafenib (investigational agent) in combination with preoperative external beam conformal radiotherapy (50 Gy in 25 fractions) for localized, large soft tissue sarcomas of the extremity and body wall prior to resection with curative intent. Sorafenib is an FDA-approved targeted agent for patients with renal cell carcinoma and hepatocellular carcinoma. Preliminary data suggest activity for sorafenib against soft tissue sarcoma in the metastatic setting. Limited data are available regarding the safety and efficacy of sorafenib in combination with radiotherapy.
The Phase I portion of the trial will seek to establish the safety of sorafenib and radiotherapy in the neoadjuvant setting for soft tissue sarcomas of the extremity and body wall. The Phase II portion of the trial will aim to determine the pathologic near-complete/complete response rate (≥ 95% tumor necrosis) of this multimodality therapy. Molecular and dynamic contrast-enhanced MRI studies will seek to establish correlative biological and imaging markers of response and/or resistance to this therapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1/Phase 2 |
Detailed Description
Patients will receive neoadjuvant sorafenib (investigational agent) in combination with preoperative external beam conformal radiotherapy (50 Gy in 25 fractions) for localized, large soft tissue sarcomas of the extremity and body wall prior to resection with curative intent. Sorafenib is an FDA-approved targeted agent for patients with renal cell carcinoma and hepatocellular carcinoma. Preliminary data suggest activity for sorafenib against soft tissue sarcoma in the metastatic setting. Limited data are available regarding the safety and efficacy of sorafenib in combination with radiotherapy.
The Phase I portion of the trial will seek to establish the safety of sorafenib and radiotherapy in the neoadjuvant setting for soft tissue sarcomas of the extremity and body wall. The Phase II portion of the trial will aim to determine the pathologic near-complete/complete response rate (≥ 95% tumor necrosis) of this multimodality therapy. Molecular and dynamic contrast-enhanced MRI studies will seek to establish correlative biological and imaging markers of response and/or resistance to this therapy.
Significant challenges exist in the treatment of patients with soft tissue sarcoma (STS) of the extremity and body wall. Major therapeutic goals for all patients include local disease-control, maximization of limb function, and avoidance of therapeutic morbidity. The standard approach for patients with STS has been based on radical resection with wide margins in combination with external beam radiation. Although local control rates in this setting range from 85 to 90%, patients remain at risk for substantial morbidity from this multimodality therapy. Furthermore, despite effective local therapy with surgery and radiation, approximately 50% of patients with high grade STS will die of disease within 5 years of diagnosis.
Experimental data and experience from other solid tumors suggest a significant synergistic effect when anti-angiogenic targeted therapies, such as sorafenib, are combined with radiotherapy (RT). Overproduction of angiogenic factors in the tumor vasculature leads to disordered/poorly regulated tumor perfusion which appears to normalize following delivery of anti-angiogenic agents. This, in turn, allows improved delivery of and susceptibility to cytotoxic agents, which is particularly important with RT since hypoxia is a key mechanism of resistance to this modality. Preliminary clinical data in rectal cancer and malignant brain tumors have demonstrated promising results from the combination of anti-angiogenic agents and RT with respect to downstaging of the primary tumor, local tumor control, and improved progression-free survival. Angiogenic factors are upregulated in patients with STS, and anti-angiogenic agents demonstrate activity against STS in the metastatic setting.
Consequently, we propose to evaluate preoperative combined modality sorafenib and conformal RT in patients with STS of the extremity and body wall in a prospective Phase I/II clinical trial. Key endpoints will be safety and toxicity in the Phase I trial and pathological response in the Phase II trial. Additional endpoints will include molecular and functional imaging correlative studies of biomarkers of response and resistance to treatment.
We hypothesize that this combination will be safe and will increase pathologic necrosis within the primary tumor at the time of surgical resection, translating into reduced volume of resected tissue, improved local disease-control, and ultimately improved disease-free survival. Functional imaging studies (dynamic contrast-enhanced MRI) and molecular examination of pre- and post-treatment tumor tissue and serum will allow correlation of changes in tumor blood flow, hypoxia transcription factors, phosphorylated ERK, and angiogenic markers to the degree of tumor necrosis following treatment with preoperative sorafenib and radiotherapy.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Phase I
|
Drug: Sorafenib
400mg twice daily
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of Dose Limiting Toxicities [Approximately 12 weeks]
Number of dose limiting toxicities and number with adverse events. Dose-escalation schedule comprising 6 to 12 patients (see schema). This sample size is based on a traditional 3+3 cohort design with escalating doses of sorafenib in combination with 50 Gy of conformal radiotherapy delivered in 25 fractions (200 cGy per fraction). Based on preclinical data regarding the radiobiology of sorafenib,33, 36 sorafenib will be initiated at a dose of 200 mg twice daily, followed by 200 mg Q AM/400 mg Q PM for the 2nd cohort, followed by 400 mg bid for the 3rd cohort. Since 400 mg bid is the well established MTD for sorafenib monotherapy in patients with renal cell carcinoma and hepatocellular carcinoma, the dose will not be escalated above this level even if DLT is not observed. Dose level escalation will be determined based on DLTs observed from initiation of sorafenib/RT until time of surgery.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed soft-tissue sarcoma located on the extremity or body wall.
-
Intermediate or High grade (NCI grade 2 or 3/3-tier system), > 5 cm in maximal dimension.
-
Low grade (NCI grade 1/3-tier system), > 8 cm in maximal dimension.
-
No evidence of regional or distant metastatic disease.
-
Patient must be 18 years of age or older.
-
Patient must have an ECOG performance status of ≤ 2.
-
Patient must have a histologic diagnosis of soft tissue sarcoma.
-
Patient must have adequate bone marrow, liver, and renal function as assessed by the following:
-
Hemoglobin ≥ 9.0 g/dl
-
Absolute neutrophil count (ANC) ≥ 1,500/mm3
-
Platelets ≥ 100,000/mm3.
-
Total bilirubin ≤ 1.5 mg/dL. NOTE: Patients with elevated bilirubin secondary to Gilbert's syndrome are eligible to participate in the study.
-
AST and ALT ≤ 2.5 times the institution upper limit of normal (ULN).
-
Creatinine ≤ 1.5 times ULN.
-
Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to the start of treatment . NOTE: Postmenopausal women must be amenorrheic for at least 12 months to be deemed not of reproductive potential.
-
Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men should use adequate birth control for at least three months after the last administration of sorafenib.
-
Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to any study specific procedures.
-
INR < 1.5 or a PT/PTT within normal limits. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable.
Exclusion Criteria:
-
Patient is receiving additional cancer-directed therapy at time of entry into trial.
-
Patient has received or is receiving preoperative investigational treatment.
-
Patient has congestive heart failure > class II NYHA. Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.
-
Patient has history of cardiac ventricular arrhythmia requiring ongoing anti-arrhythmic therapy.
-
Patient has uncontrolled hypertension, defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management.
-
Patient has known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
-
Patient has active clinically serious infection > CTCAE Grade 2.
-
Patient has thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.
-
Patient has history of pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug.
-
Patient has history of any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug.
-
Patient has history of clinical or laboratory evidence of bleeding diathesis or coagulopathy.
-
Patient has history of major surgery or significant traumatic injury within 4 weeks of first study drug.
-
Patient has concomitant use of St. John's Wort or rifampin (rifampicin).
-
Patient has known or suspected allergy to sorafenib or any agent given in the course of this trial.
-
Patient has any condition that impairs his or her ability to swallow whole pills.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of california, Davis Medical Center | Sacramento | California | United States | 95817 |
Sponsors and Collaborators
- University of California, Davis
- Bayer
Investigators
- Principal Investigator: Robert Canter, MD, U C Davis Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STS Sorafenib
- NCT00805727
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Sorafenib 200/200 | Sorafenib 200/400 | Sorafenib 400/400 |
|---|---|---|---|
| Arm/Group Description | Dose level 1 sorafenib 200 bid with concurrent neoadjuvant radiation therapy. sorafenib administered orally. agent administered during concurrent neoadjuvant radiation therapy. both modalities discontinued approximately 4 - 6 weeks prior to surgical resection with curative intent. | Dose level 2 sorafenib 200 mg PO Q AM and 400 mg PO Q PM with concurrent neoadjuvant radiation therapy. sorafenib administered orally. agent administered during concurrent neoadjuvant radiation therapy. both modalities discontinued approximately 4 - 6 weeks prior to surgical resection with curative intent. Traditional 3+3 dose escalation Phase I trial. Cohort 2 enrolled after completion of all 3 participants in dose level 1. | Dose level 3 sorafenib 400 mg PO BID with concurrent neoadjuvant radiation therapy. sorafenib administered orally. agent administered during concurrent neoadjuvant radiation therapy. both modalities discontinued approximately 4 - 6 weeks prior to surgical resection with curative intent. |
| Period Title: Overall Study | |||
| STARTED | 3 | 5 | 0 |
| COMPLETED | 3 | 5 | 0 |
| NOT COMPLETED | 0 | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | Phase I |
|---|---|
| Arm/Group Description | |
| Overall Participants | 8 |
| Age (Count of Participants) | |
| <=18 years |
0
0%
|
| Between 18 and 65 years |
7
87.5%
|
| >=65 years |
1
12.5%
|
| Age (years) [Mean (Standard Deviation) ] | |
| Mean (Standard Deviation) [years] |
44
(12)
|
| Sex: Female, Male (Count of Participants) | |
| Female |
5
62.5%
|
| Male |
3
37.5%
|
| Region of Enrollment (participants) [Number] | |
| United States |
8
100%
|
Outcome Measures
| Title | Number of Dose Limiting Toxicities |
|---|---|
| Description | Number of dose limiting toxicities and number with adverse events. Dose-escalation schedule comprising 6 to 12 patients (see schema). This sample size is based on a traditional 3+3 cohort design with escalating doses of sorafenib in combination with 50 Gy of conformal radiotherapy delivered in 25 fractions (200 cGy per fraction). Based on preclinical data regarding the radiobiology of sorafenib,33, 36 sorafenib will be initiated at a dose of 200 mg twice daily, followed by 200 mg Q AM/400 mg Q PM for the 2nd cohort, followed by 400 mg bid for the 3rd cohort. Since 400 mg bid is the well established MTD for sorafenib monotherapy in patients with renal cell carcinoma and hepatocellular carcinoma, the dose will not be escalated above this level even if DLT is not observed. Dose level escalation will be determined based on DLTs observed from initiation of sorafenib/RT until time of surgery. |
| Time Frame | Approximately 12 weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Sorafenib 200/200 | Sorafenib 200/400 |
|---|---|---|
| Arm/Group Description | ||
| Measure Participants | 3 | 5 |
| Number [DLTs] |
0
|
2
|
Adverse Events
| Time Frame | ||||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Sorafenib 200/200 | Sorafenib 200/400 | ||
| Arm/Group Description | Dose level 1. Sorafenib 200 mg PO BID | Dose level 2. Sorafenib 200 mg PO Q AM and 400 mg PO Q PM | ||
All Cause Mortality |
||||
| Sorafenib 200/200 | Sorafenib 200/400 | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
| Sorafenib 200/200 | Sorafenib 200/400 | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/3 (0%) | 2/5 (40%) | ||
| Skin and subcutaneous tissue disorders | ||||
| rash | 0/3 (0%) | 0 | 2/5 (40%) | 2 |
Other (Not Including Serious) Adverse Events |
||||
| Sorafenib 200/200 | Sorafenib 200/400 | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 2/3 (66.7%) | 3/5 (60%) | ||
| Blood and lymphatic system disorders | ||||
| anemia | 0/3 (0%) | 0 | 1/5 (20%) | 1 |
| Cardiac disorders | ||||
| Hypertension | 1/3 (33.3%) | 1 | 1/5 (20%) | 1 |
| Nervous system disorders | ||||
| Hand-Foot syndrome | 1/3 (33.3%) | 1 | 1/5 (20%) | 1 |
| Skin and subcutaneous tissue disorders | ||||
| perirectal abscess | 0/3 (0%) | 0 | 1/5 (20%) | 1 |
| Rash | 1/3 (33.3%) | 1 | 0/5 (0%) | 0 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
| Name/Title | Dr. Robert J. Canter |
|---|---|
| Organization | University of California Davis Comprehensive Cancer Center |
| Phone | 916-734-5907 |
| robert.canter@ucdmc.ucdavis.edu |
- STS Sorafenib
- NCT00805727